Study to measure the impact of whole genome sequencing in patients with cardiovascular disease

Henry Ford Health research teams are launching a series of clinical studies in partnership with Illumina Inc., a global leader in DNA sequencing and array-based technologies, to assess the impact of comprehensive genomic testing in various disease areas.

Related Keywords

United States ,Herb Aronow ,Phil Febbo ,Emily Henderson ,David Lanfear ,American College Of Medical Geneticists ,World Health Organization ,Translational Research At Henry Ford Health ,Henry Ford Health ,Drug Administration ,Heart Vascular Services At Henry Ford Health ,Clinical Pharmacogenetics Implementation Consortium ,Christopher Jeffries Center ,Genomic Medicine Research At Henry Ford Health ,Illumina Inc ,Ford Health ,Cardiovascular Medicine ,Henry Ford ,Precision Medicine ,Genomic Medicine Research ,Vice President ,Translational Research ,Medical Director ,Vascular Services ,Chief Medical Officer ,American College ,Medical Geneticists ,Genomic ,Heart ,Heart Disease ,Dancer ,Cardiovascular Disease ,Na ,Na Sequencing ,Genes ,Enetic ,Enome ,Genomics ,Health Care ,Healthcare ,Illumina ,Medicine ,Rthopedics ,Research ,Sports Medicine ,Whole Genome Sequencing ,